Analyzing Semperit Ag Hld (OTCMKTS:SEIGY) & TriSalus Life Sciences (NASDAQ:TLSI)

Semperit Ag Hld (OTCMKTS:SEIGYGet Free Report) and TriSalus Life Sciences (NASDAQ:TLSIGet Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Valuation & Earnings

This table compares Semperit Ag Hld and TriSalus Life Sciences”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Semperit Ag Hld $732.20 million 0.42 $12.44 million ($0.10) -37.60
TriSalus Life Sciences $29.43 million 9.23 -$30.05 million ($2.02) -2.69

Semperit Ag Hld has higher revenue and earnings than TriSalus Life Sciences. Semperit Ag Hld is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. 27.5% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Semperit Ag Hld and TriSalus Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Semperit Ag Hld -0.58% -0.89% -0.42%
TriSalus Life Sciences -98.45% N/A -111.88%

Risk and Volatility

Semperit Ag Hld has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Semperit Ag Hld and TriSalus Life Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Semperit Ag Hld 0 0 0 0 0.00
TriSalus Life Sciences 1 1 2 0 2.25

TriSalus Life Sciences has a consensus target price of $11.00, suggesting a potential upside of 102.21%. Given TriSalus Life Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than Semperit Ag Hld.

Summary

TriSalus Life Sciences beats Semperit Ag Hld on 9 of the 14 factors compared between the two stocks.

About Semperit Ag Hld

(Get Free Report)

Semperit Aktiengesellschaft Holding develops, produces, and sells rubber products for the medical and industrial sectors worldwide. It operates through two segments: Semperit Industrial Applications and Semperit Engineered Applications. The company provides hydraulic and industrial hoses; conveyor belts; escalator handrails; profiles for windows, doors and facades, cable car rings, and ski foils; and products for railroad superstructures and toolmaking; and precision liquid silicone parts. It offers handrails; engineered solutions; and provides elastomer and sealing profiles for windows, doors, and facades; and elastomer and wear-resistant protective sheeting. It serves agriculture, bulk transportation systems, construction, manufacturing, health care, mining and port facilities, shipping, packing, household, renewable energy and power generation, process, steel, and automotive industries. Semperit Aktiengesellschaft Holding was founded in 1824 and is headquartered in Vienna, Austria.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Receive News & Ratings for Semperit Ag Hld Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semperit Ag Hld and related companies with MarketBeat.com's FREE daily email newsletter.